Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CoFactor and 5-FU in Metastatic Colorectal Carcinoma
NCT00081627Phase 2Completed
- Sponsor
- Mast Therapeutics, Inc.
- Start
- Apr 2004
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of folitixorin in metastatic colorectal cancer (mCRC), sponsored by Mast Therapeutics, Inc. Primary endpoints: Efficacy of CoFactor and 5-FU and Safety of CoFactor and 5-FU. Started Apr 2004; status: completed.
02
Drugs
folitixorin
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00081627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00081627.